The publication of positive Phase 3 clinical trial results in the New England Journal of Medicine is a significant milestone for AbbVie's upadacitinib. The drug's approval in multiple countries, including the US, indicates strong potential for increased revenue and market share in the Crohn's disease treatment market. This is likely to have a positive short-term impact on AbbVie's stock price.